Here, the identification of DSG2 (Desmoglein 2) as a dominant counter receptor of Siglec‐9 in melanoma cells is reported, using a workflow that combines the strength of proximity labeling and the advantage of CRISPR knockout screening. Here, SIGLEC9 is linked to melanoma.